Arrival of Large Bore Venous Transcatheter Therapies Amplifying the Need for Efficient Closure

The current influx of regulatory approvals for transcatheter interventions requiring large bore venous access is highlighting the absence of quick efficient vascular perforation closure. Current options for closure are either tedious and lengthy manual compression, or off-label workarounds with multiple small-bore closure devices. Venock's dedicated large bore closure device will respond to this unmet need in the market by providing immediate and efficient closure of large bore venous access sites, enhancing patient comfort while providing significant cost savings and efficiency to the cathlab. Regulatory approval of the device is forthcoming.

The recent US and EU regulatory approvals of leadless pacemakers (Medtronic's Micra and Abbott's Avier), as well as the tricuspid valve replacement system (Edwards's EVOQUE), and most recently the tricuspid valve repair system (Abbott's Triclip) are an early indication of the influx of large bore venous transcatheter therapies coming to market.

The only way to close these access sites is either manual compression (sometimes with a "Figure of 8" stitch), or off-label workarounds with multiple closure devices which are indicated for small bore sites. Dr Richard R. Heuser, a widely renowned cardiologist and professor of Medicine of the University of Arizona affirms, "Venous procedures using large bore catheters are becoming more and more common, particularly as we work on tricuspid valves and other structural heart problems. It's been my experience, that the only devices out there are currently used off-label and are very inconvenient. You have to prepare closure before the procedure and it sometimes requires multiple different closure devices, which makes the procedure expensive."

The archaic process of manual compression is time consuming (requiring hours of recovery time), thus expensive, and very burdensome for the patient. This process slows down discharge and patient turnover, negatively affecting the number of therapies which can be done per day and thus overall efficiency. Additionally, the use of multiple small-bore devices not only increases procedural time and cost, but also adds unnecessary complexity to the closure procedure.

Venock's dedicated large bore closure device (Figure 1) will respond to this unmet need in the market by providing quick efficient closure in 1 minute, removing the need for the 6 to 8 hours of bedrest, enhancing patient comfort while providing significant cost savings and efficiency to the cathlab.

Dr Richard R. Heuser agrees: "Venock is a one stop shopping device that is cost-effective and importantly will reduce time in the outpatient center or the hospital with cost savings for Medicare, health plans as well as the hospital and outpatient center."

More:
www.venock.com
www.venock.com/index.php/whitepaper.html

CAUTION: The Venock system is not approved for sale or investigational use.

VENOCK INC.
Terry Barnes, CEO
521 Fifth Avenue, Floor 17
New York, NY 10175 - USA
Email: terry.barnes@venock.com
Mobile: +49 170 557 0073
www.venock.com

Venock Inc. is a privately held US medical device company headquartered in New York City, with the subsidiary Venock Medical GmbH in Munich, Germany. Its Vascular Closure Device is designed to close very large perforations that can be as big as the diameter of the vein or the artery.

This release was published on openPR.